Kornimate/medical-research-clean huggingface dataset:
synbiotic as an adjunct to mechanical treatment of gingivitis

Conditions: Gingivitis; Chronic; Smoking

Summary: the aim of this study is to evaluate the efficacy of oral administration of synbiotic tablets on the clinical parameters and the levels of selected inflammatory mediators in gingival crevicular fluid (gcf) in smokers and non-smokers with gingivitis. this study designed as a double-blind randomized placebo-controlled clinical trial.

some patients like smokers have ongoing host response even after bacterial plaque removal achieved. therefore efforts to develop effective treatment approaches remain an important objective in the treatment of gingivitis to prevent periodontitis especially in patients at high risk for developing periodontitis as smokers. smoking is a major risk factor for the incidence and the progression of periodontal diseases. the increased periodontal disease susceptibility in smokers is predominantly caused by changes in inflammatory and immune responses. cigarette smoking also influences the amount and the composition of subgingival plaque. smokers have higher numbers of pathogens in their resident biofilm and display an ongoing host response even after biofilm removal. different approaches were explored to reduce the negative effects of smoking on the outcomes of periodontal therapy synbiotic were defined as a mixture of probiotics and prebiotics that beneficially affects the host by improving the survival and implantation of live microbial dietary supplements in the gastrointestinal tract, by selectively stimulating the growth and/or by activating the metabolism of one or a limited number of health-promoting bacteria, and thus improving host welfare. also in some cases, this may lead to a competitive advantage for the probiotics among with other bacteria.

Eligibility criteria:
inclusion criteria: * systemically healthy subjects * clinical diagnosis of gingivitis exclusion criteria: * subjects who had used any systemic antibiotics in the previous 3 months, * subjects who had used a product containing probiotics in the previous month * systemic disease or condition that could interfere with the study results * ongoing drug therapy that could affect the signs of gingivitis * subjects who were received periodontal treatment in the last 6 months and * allergic to milk and milk products

Keywords: gingivitis gingival crevicular fluid probiotics smoking periodontal medicine
incentive spirometry added to physiotherapy to reduce postoperative pulmonary complications after lung surgery

Conditions: Lung Neoplasms; Benign Lung Disease

Summary: after any surgery, there is a chance of complications. after lung surgery to remove tumours, there is a particularly high chance of a person developing an infection or needing help breathing, called post operative pulmonary complications. currently, the risk of these complications is reduced through the completion of light physical and deep breathing exercises and walking around as soon as possible after surgery. another possible way of helping these patients is to use a small device called an incentive spirometer to encourage and measure deep breathing. this study wants to compare how often postoperative pulmonary complications happen after major lung surgery between a group completing the exercises alone and a group using the incentive spirometer in addition to the exercises. it is hoped that the combined therapy will reduce the amount of time patient must stay in hospital, have fewer complication events and have fewer patients re-admitted back into the hospital after they go home, so that patients overall have better outcomes.

this study is a prospective blinded randomized control trial (rct) where two arms will be assembled. consenting eligible patients will be randomized to either the physiotherapy + incentive spirometry (pt+is-intervention) arm or physiotherapy only (pt-control arm). patients will be randomized with an equal (1:1) chance of being allocated to either the pt (control) arm or pt+is (intervention) arm. both the treating surgeon and data interpreter will be blinded to the intervention.

Eligibility criteria:
inclusion criteria: * patients must be at minimum age 18 * patient must be undergoing pulmonary resection surgery for malignant or benign disease * patients must be able to understand english * patients must be able to demonstrate aptitude and willingness to comply with describes study procedures exclusion criteria: * patients who are unable to read and communicate in english * home oxygen usage prior to operation * previous pulmonary resection or any thoracic surgery * radiological evidence of atelectasis or pneumonitis on preoperative imaging * radiological evidence of pleural effusion prior on preoperative imaging * prior exposure to pulmonotoxic drugs such as amiodarone or belomycin * current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. * inability or unwillingness of individual or legal guardian/representative to give written informed consent

Keywords: lung resection incentive spirometry physiotherapy quality improvement outcomes post operative complications
topical ocular mecamylamine in diabetic macular edema (dme)

Conditions: Diabetic Macular Edema

Summary: this is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (dme). patients will be treated for 12 weeks.


Eligibility criteria:
inclusion criteria: * macular edema due to diabetic retinopathy exclusion criteria: * vision loss from other ocular disease * intraocular surgery within 3 months * intraocular anti-vegf or steroids within 3 months * hba1c \>12

Keywords: macular edema dme diabetic mecamylamine comentis
open label, zonegran (zonisamide) in partial onset seizures

Conditions: Epilepsy

Summary: to determine the efficacy and safety of adjunctive open label zonegran treatment in patients with refractory partial seizures.


Eligibility criteria:
inclusion criteria: 1. male or female patients aged 18-75. 2. able and willing to give written informed consent in accordance with the ich gcp guidelines. 3. female subjects of childbearing potential must not be pregnant (as confirmed by negative serum βhcg at screening and negative urine pregnancy test at baseline/during the study), must not be lactating and must use a medically acceptable form of contraception during the study and for at least 1 month after discontinuation of study drug. medically acceptable contraception as defined here is the oral contraceptive pill, surgical sterilization or hormonal intrauterine device in place for at least 3 months. women who are less than 2 years post-menopausal are considered to be of childbearing potential. 4. focal epilepsy, with simple and/or complex partial seizures with or without secondary generalized seizures as defined by the ilae criteria. 5. patients with a minimum of 4 partial seizures in the 8 weeks preceding the baseline visit as adequately recorded using a seizure diary card. 6. patients should be receiving at least 1 but no more than 2 other aeds as concomitant medication, and the dosage should be stable for at least 8 weeks before the baseline visit. exclusion criteria: 1. history of status epilepticus within the last 5 years. 2. patients with known significantly impaired renal function and/or severe hepatic impairment to the extent that the protocol dose titration schedule cannot be followed. note investigators should consult included smpc as a guide. 3. patients suffering from clinically significant psychiatric illness, psychological or behavioral problems which could interfere with study participation. 4. patients with a history (within the last 12 months) of alcohol or drug abuse or dependency. 5. patient suffering from any cns progressive disease that may confound study interpretation, any active cns infection, demyelinating disease or degenerative neurological disease. 6. patients with a significant drug sensitivity or significant allergic reaction to any drug including sulfonamides. 7. subjects considered by the investigator to be an unsuitable candidate for receiving zonegran or considered unlikely to comply with the protocol. 8. any patient contraindicated for zonegran treatment as per attached smpc. 9. any patient who is pregnant and/or lactating.
assessment of the sexuality of the infertile couple

Conditions: Infertility

Summary: the study hypothesis is that infertile couples experience an impact of their sexuality impacted during the diagnostic process carried out as part of the medically assisted procreation assessment, and also by the announcement of the possible cause of the couple's infertility. it is also conceivable that a disorder of the couple's sexuality forms the origin of, or is a contributor to, infertility.


Eligibility criteria:
inclusion criteria: * couple in which each of the two partners has signed the consent form which is presented separately and independently of their partner. * the patient must be a member or beneficiary of a health insurance plan * heterosexual infertile couple (according to the who definition) monitored at the nîmes university hospital in the urology / gynecology departments. adult patient (≥18 years old) and under 43 years old for women, 60 years old for men exclusion criteria: * the subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study * one member of the couple refuses to sign the consent * it is impossible to give the subject informed information * the patient is under safeguard of justice or state guardianship * patient without good level of written and spoken french
artificial intelligence and dysplasia detection in inflammatory bowel disease (eiidisia study)

Conditions: Inflammatory Bowel Diseases; Dysplasia

Summary: randomized clinical study analyzing the efficacy of colonoscopy assisted by the computer aided detection (cade) system compared to virtual chromoendoscopy with narrow band imaging (nbi) in the detection of colon dysplasia in patients with long-standing inflammatory bowel disease (ibd).


Eligibility criteria:
inclusion criteria: * adults (age ≥18 years). * patients with ibd meeting the following criteria: * diagnosis of ibd confirmed by clinical and histological evidence. * disease extent (montreal classification): 1) for ulcerative colitis (uc), extensive colitis (e3): involvement proximal to the splenic flexure; or, left-sided colitis (e2): involvement distal to the splenic flexure. 2) for crohn's disease (cd): colon-only involvement (l2); or, ileocolonic involvement (l3). * disease duration \> 7 years. * patients with concommitant primary sclerosing cholangitis, regardless of the extent of colonic involvement and disease duration. * written consent from the patient to undergo colonoscopy (signed informed consent). exclusion criteria: * personal history of colorectal cancer (crc). * previous colectomy (partial or complete). * coagulopathy preventing biopsy or polypectomy/mucosal resection. * colonoscopy performed in the last 6 months. * pregnant or lactating women. * ulcerative colitis with involvement limited to the rectum or proctitis (montreal e1). * inadequate colonic preparation due to uncleavable fecal residue during colonoscopy: boston bowel preparation scale (bbps) = 0 or 1 in any colon segment. * presence of inflammatory activity due to ibd on endoscopy:1) for uc: endoscopic mayo score ≥ 2. 2) for cd: simplified endoscopic activity score (ses-cd) \> 5. * incomplete lower digestive endoscopy (failure to reach the cecum).

Keywords: inflammatory bowel disease virtual chromoendoscopy nbi cade dysplasia
traditional tibetan medicine for patients with coronary artery disease

Conditions: Coronary Artery Disease

Summary: coronary artery disease has a high death toll in the western world. changes in lifestyle, particularly in nutrition and physical activity may significantly reduce a severe coronary atherosclerosis within one year without the use of medication. several dietary studies have shown that not only the progress of coronary artery disease can be slowed down, but it may also increase significantly the survival of these patients. up until now there is little known about therapeutic effects by complementary medicine. in particular, traditional tibetan medicine dietary programs have shown in few case reports that weight could be reduced in patients with obesity. therefore, the investigators developed a specific dietary program for patients with coronary artery disease, who have an increased cardiovascular risk profile according to the criteria by the international diabetes federation (idf).


Eligibility criteria:
inclusion criteria: * \>= 18 years old * male and female * coronary artery disease * criteria of international diabetes federation (idf) exclusion criteria: * \<18 years old * incapability for informed consent * history of malignity, psychiatric disorder, tissue, thyroid gland and renal diseases, anorexia or bulimia * administration of steroids or hormones * pregnancy * body mass index \< 25

Keywords: dietary, behavior idf criteria coronary artery disease traditional tibetan medicine coronary artery disease in patients, who have an increased cardiovascular risk profile according to the criteria by the international diabetes federation (idf)
a research study looking at how oral semaglutide works in people with type 2 diabetes in saudi arabia, as part of local clinical practice

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of the study is to collect information on how rybelsus® works in people with type 2 diabetes and to see if rybelsus® can lower their blood sugar levels. participants will get rybelsus® as prescribed to them by the study doctor. the study will last for about 8-10 months. participants will be asked to complete a questionnaire about how they take their rybelsus® tablets. participants will complete this questionnaire during their normally scheduled visit with the study doctor.


Eligibility criteria:
inclusion criteria: 1. signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) 2. diagnosed with type 2 diabetes mellitus 3. the decision to initiate treatment with commercially available oral semaglutide has been made by the patient/legally acceptable representative (lar) and the treating physician based on local label before and independently from the decision to include the patient in this study 4. male or female, age above or equal to 18 years at the time of signing informed consent 5. available hba1c value below or equal to 90 days prior to the 'informed consent and treatment initiation visit' (v1) or hba1c measurement taken in relation with the 'informed consent and treatment initiation visit' (v1) if in line with local clinical practice 6. treatment naïve to injectable glucose-lowering drug(s). an exception is short-term insulin treatment for acute illness for a total of below 14 days exclusion criteria: 1. previous participation in this study. participation is defined as having given informed consent in this study 2. treatment with any investigational drug within 30 days prior to enrolment into the study 3. mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
gravity flow technique to validate proper location of epidural needle tip on obese parturients

Conditions: Epidural/Anesthesia

Summary: pregnant women, with a body mass index (bmi) greater than 30 kg/m2, who receive epidural analgesia/anesthesia for childbirth will have epidural catheter placement per our standard procedure, which includes using the gravity flow technique to confirm that the tip (aperture) of the epidural needle is indeed located within the epidural space. the study procedure will be to use a cold stimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen between 10 and 30 minutes after the epidural catheter is inserted. hypesthesia to cold will be taken a sign of successful lumbar epidural block.

the purpose of this study is to quantify the reliability of the gravity flow technique to accurately validate the position of the epidural needle tip when performing lumbar epidural analgesia/anesthesia for childbirth (vaginal and cesarean delivery) in women with a bmi greater than 30 kg/m2.

Eligibility criteria:
inclusion criteria: * patients requesting epidural analgesia/anesthesia for childbirth * american society of anesthesiologists (asa) physical status i to iii * ability to speak and read english to fully comprehend the consent process * bmi greater than 30 kg/m2 exclusion criteria: * combined spinal-epidural anesthesia * coagulopathy * history of lumbar spine surgery * allergy or contraindication to any of the study medications * contraindication to epidural analgesia * asa physical status \>iii * bmi less than 30 kg/m2

Keywords: epidural
early psychological intervention after rape

Conditions: Post Traumatic Stress Disorder

Summary: the aim of the study is to translate and adapt a brief treatment protocol based on prolonged exposure provided within 72 hours after a rape to a swedish context and pilot test feasibility and delivery in ten executive patients recruited at the emergency clinic for rape victims in stockholm.

the aim of the study is to translate and adapt a brief treatment protocol based on prolonged exposure provided within 72 hours after a rape to a swedish context and pilot test feasibility and delivery in ten executive patients recruited at the emergency clinic for rape victims in stockholm. endpoints the posttraumatic stress disorder checklist for dsm-5 (pcl-5), beck depression inventory (bdi) at baseline and post-treatment. insomnia severity index (isi) , multidimensional scale of perceived social support (mspss), world health organization disability assessment schedule(whodas-12) at post-treatment.the clinician-administered ptsd scale for dsm-5 (caps-5) at follow up. data on feasibility aspects of the intervention will also be collected: compliance to the intervention/homework/assessments, possibilities to recruit, adverse events. recruitment the investigatorors will recruit ten consecutive patients attending at the emergency clinic for rape victims at stockholm south hospital, sweden. safety parameters participants had the opportunity to report any adverse events during treatment, at posttreatment and follow-up.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * attending at the emergency clinic for rape victims at stockholm south hospital, sweden within 72 hours after experiencing a rape) * remembered the event. exclusion criteria: * ongoing suicidal ideation or attempted suicide within the last two months * ongoing self-harm behavior * ongoing intoxication * other serious psychiatric comorbidity (ongoing psychotic symptoms or manic episode) * low cognitive capacity * not fluent in swedish * subjected to ongoing violence or threat
observational study of neurofilament light chain (nfl) as a biomarker in asymptomatic carriers of the transthyretin (ttr) variants and patients with hereditary transthyretin-mediated (hattr) amyloidosis with polyneuropathy

Conditions: Hereditary Amyloidosis, Transthyretin-Related; Asymptomatic Carrier State

Summary: this is a single-center observational study evaluating the potential value of nfl as a biomarker for diagnosis, detection of disease onset, monitoring of disease progression, and treatment response in asymptomatic carriers of ttr variants and symptomatic hattr amyloidosis patients with polyneuropathy.

in this study, participants' data will be extracted from their medical records or collected based on clinical and laboratory assessments during routine visits, per the site's standard of care. blood samples collected from the participants during routine visits will also be used for analysis. the study will be conducted in two parts: cross-sectional part during which a single measurement of nfl levels will be performed using blood samples collected from asymptomatic carriers, and symptomatic hattr amyloidosis patients; longitudinal part during which measurements of nfl levels will be performed over time using blood samples (already collected from the participants during routine visits) from asymptomatic carriers and patients with symptomatic hattr amyloidosis.

Eligibility criteria:
inclusion criteria: - carrier of a documented pathogenic ttr variant confirmed with genotyping with predicted disease onset within 5 years and not diagnosed with hattr amyloidosis with polyneuropathy or confirmed diagnosis of hattr amyloidosis with polyneuropathy with a documented ttr variant confirmed with genotyping - participant is able to understand the study and does not oppose participating in the study after reviewing the content of the pis provided. exclusion criteria: * a known condition (other than hattr amyloidosis) that can cause nerve damage and affect nfl levels * estimated glomerular filtration rate (egfr) \<45 milliliters per minute per 1.73 meters squared (ml/min/1.73 m\^2) * currently enrolled in a clinical study for any investigational agent.
accuracy of scanwatch pulse oximeter with profound hypoxia

Conditions: Oximetry

Summary: performance testing of pulse oximeters. the protocol involves brief stable arterial oxygen desaturation in healthy volunteers and sampling arterial blood when a stable level of hypoxia has been attained. the blood sample is analyzed for oxygen saturation with a gold standard bench co-oximeter. this protocol is aligned with the latest iso and fda guidance documents for pulse oximeter testing.


Eligibility criteria:
inclusion criteria: * the subject is male or female, aged ≥18 and \<50. * the subject is in good general health with no evidence of any medical problems. * the subject has both wrist circumferences between 14 and 22cm. * the subject has provided informed consent and is willing to comply with the study procedures. exclusion criteria: * the subject is obese (bmi\>30). * the subject has a known history of heart disease, lung disease, kidney or liver disease. * diagnosis of asthma, sleep apnea, or use of cpap. * subject has diabetes. * subject has a clotting disorder. * the subject a hemoglobinopathy or history of anemia, per subject report or the first blood sample that in the opinion of the investigator, would make them unsuitable for study participation. * the subject has any other serious systemic illness. * the subject is a current smoker. * the subject has piercings that may cause air leaks during the test * the subject has any injury, deformity, or abnormality at the sensor sites that in the opinion of the investigators' would interfere with the sensors working correctly. * the subject has a history of fainting or vasovagal response. * the subject has a history of sensitivity to local anesthesia. * the subject has a diagnosis of raynaud's disease. * the subject has unacceptable collateral circulation based on exam by the investigator (allen's test). * the subject is pregnant, lactating or trying to get pregnant. * the subject is unable or unwilling to provide informed consent, or is unable or unwilling to comply with study procedures. * the subject has a resting heartrate over 120, systolic bp is over 150, diastolic bp is over 90 or room air spo2 is less than 94%. * the subject has carboxyhemoglobin over 3% as measured by lab blood gas analysis. * the subject has any other condition, which in the opinion of the investigators' would make them unsuitable to participate.